Evidence map›Paper›PMID 37368350›Full record

ArticleThe oncologist2023

Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort.

Nikolaus Christian Simon Mezger, Lucia Hämmerl, Mirko Griesel, Tobias Paul Seraphin, Yvonne Walburga Joko-Fru, Jana Feuchtner, Annelle Zietsman, Jean-Félix Péko, Fisihatsion Tadesse, Nathan Gyabi Buziba and 14 more

Open access · goldAbstract read
In one paragraph

Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 12 institutions in 10 countries.

Nikolaus Christian Simon MezgerGlobal Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle, Germany.ORCID 0000-0002-5090-1080
Lucia HämmerlGlobal Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Mirko GrieselGlobal Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Tobias Paul SeraphinGlobal Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Yvonne Walburga Joko-FruAfrican Cancer Registry Network, Oxford, UK.
Jana FeuchtnerGlobal Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Annelle ZietsmanAfrican Cancer Registry Network, Oxford, UK.
Jean-Félix PékoAfrican Cancer Registry Network, Oxford, UK.
Fisihatsion TadesseAfrican Cancer Registry Network, Oxford, UK.
Nathan Gyabi BuzibaAfrican Cancer Registry Network, Oxford, UK.
Henry WabingaAfrican Cancer Registry Network, Oxford, UK.
Mary NyanchamaAfrican Cancer Registry Network, Oxford, UK.
Eric ChokunongaAfrican Cancer Registry Network, Oxford, UK.
Mamadou KéitaAfrican Cancer Registry Network, Oxford, UK.
Guy N'daAfrican Cancer Registry Network, Oxford, UK.
Cesaltina Ferreira LorenzoniAfrican Cancer Registry Network, Oxford, UK.
Marie-Thérèse Akele-AkpoAfrican Cancer Registry Network, Oxford, UK.
Jörg Michael MezgerAlbert-Ludwig University of Freiburg, Germany.
Mascha BinderDepartment of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Biying LiuAfrican Cancer Registry Network, Oxford, UK.
Marcus BauerInstitute of Pathology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Oliver HenkeSection Global Health, Institute for Public Health and Hygiene, University Hospital Bonn, Germany.
Ahmedin JemalSurveillance and Health Equity Science, American Cancer Society, Atlanta, USA.ORCID 0000-0002-0000-4111
Eva Johanna KantelhardtGlobal Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle, Germany.ORCID 0000-0001-7935-719X
Martin Luther University Halle-Wittenberg · DENational Cancer Registration Service · GBAmerican Cancer Society · USEduardo Mondlane University · MZKenya Medical Research Institute · KEMinistre de la Santé · BJMoi University · KENational Blood Service Zimbabwe · ZWUniversity Hospital Bonn · DEUniversity of Bamako · MLUniversity of Freiburg · DEUniversity of Oxford · GB

Funding

American Cancer Society 43359German International Cooperation 13.2238.7-004.41German Ministry for Economic and Development Cooperation
6 · The paper itself

Abstract

backgroundAlthough non-Hodgkin lymphoma (NHL) is the 6th most common malignancy in Sub-Saharan Africa (SSA), little is known about its management and outcome. Herein, we examined treatment patterns and survival among NHL patients.

methodsWe obtained a random sample of adult patients diagnosed between 2011 and 2015 from 11 population-based cancer registries in 10 SSA countries. Descriptive statistics for lymphoma-directed therapy (LDT) and degree of concordance with National Comprehensive Cancer Network (NCCN) guidelines were calculated, and survival rates were estimated.

findingsOf 516 patients included in the study, sub-classification was available for 42.1% (121 high-grade and 64 low-grade B-cell lymphoma, 15 T-cell lymphoma and 17 otherwise sub-classified NHL), whilst the remaining 57.9% were unclassified. Any LDT was identified for 195 of all patients (37.8%). NCCN guideline-recommended treatment was initiated in 21 patients. This corresponds to 4.1% of all 516 patients, and to 11.7% of 180 patients with sub-classified B-cell lymphoma and NCCN guidelines available. Deviations from guideline-recommended treatment were initiated in another 49 (9.5% of 516, 27.2% of 180). By registry, the proportion of all patients receiving guideline-concordant LDT ranged from 30.8% in Namibia to 0% in Maputo and Bamako. Concordance with treatment recommendations was not assessable in 75.1% of patients (records not traced (43.2%), traced but no sub-classification identified (27.8%), traced but no guidelines available (4.1%)). By registry, diagnostic work-up was in part importantly limited, thus impeding guideline evaluation significantly. Overall 1-year survival was 61.2% (95%CI 55.3%-67.1%). Poor ECOG performance status, advanced stage, less than 5 cycles and absence of chemo (immuno-) therapy were associated with unfavorable survival, while HIV status, age, and gender did not impact survival. In diffuse large B-cell lymphoma, initiation of guideline-concordant treatment was associated with favorable survival.

interpretationThis study shows that a majority of NHL patients in SSA are untreated or undertreated, resulting in unfavorable survival. Investments in enhanced diagnostic services, provision of chemo(immuno-)therapy and supportive care will likely improve outcomes in the region.

Indexed as

Lymphoma, Large B-Cell, DiffuseLymphoma, T-CellLymphoma, T-Cell, PeripheralAdultHumansSurvival RateTreatment Outcome

Identifiers

PMID37368350
PMCPMC10628567
OpenAlexW4382182530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.